







WELCOME

Non-invasive, rapid diagnostics tests are advancing to help manage outbreaks and emerging pathogens. Immunotherapy biomarkers and companion diagnostics are vital tools for the pharma and biotech industries, and the implementation of these tests will ensure the safety and viabilities of these essential therapies.

For more than a decade, 800 industry professionals have considered the **Next Generation Dx Summit** a nexus for key decision and policy-makers, academic and industry leaders to learn the latest technologies, assays, sample prep and detection methods, analysis and machine-learning approaches that drive innovation. Regulatory and reimbursement solutions will be featured that are critical to the implementation of value-based care.

Conference At-A-Glance

STREAM		August 25 - 26 Tuesday - Wednesday AM PART A CONFERENCES	August 26 - 27 Wednesday PM - Thursday PART B CONFERENCES
POCT TECHNOLOGIES AND STRATEGY		Enabling Point-of-Care Diagnostics	Point-of-Care Technologies
POCT AND INFECTIOUS DISEASE		Enabling Point-of-Care Diagnostics	Advanced Diagnostics for Infectious Disease
LIQUID BIOPSY/EARLY DETECTION		Enabling Technologies for Liquid Biopsy	Early Detection of Disease
COMPANION DX AND IO BIOMARKERS		Drug-Diagnostics Co-Development & Companion Dx	Immuno-Oncology Biomarkers and Diagnostics
BUSINESS		Coverage and Reimbursement	Commercialization of Diagnostic Tests
NGS ADVANCES			NGS Advances and Multimodality Assays



#NGDx20

NextGenerationDx.com